View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

The Lovesac Company Announces Participation in Upcoming Investor Confe...

The Lovesac Company Announces Participation in Upcoming Investor Conference STAMFORD, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, announced today that the Company is scheduled to participate in the 2025 Global Consumer & Retail Conference hosted by Telsey Advisory Group in collaboration with Santander Corporate & Investment Banking on Wednesday, October 8, 2025, at 3:30 p.m. Eastern Time. The fireside chat will be w...

 PRESS RELEASE

The Lovesac Company Reports Second Quarter Fiscal 2026 Financial Resul...

The Lovesac Company Reports Second Quarter Fiscal 2026 Financial Results Q2 FY26 Net Sales Increased 2.5% to $160.5 Million vs. Q2 FY25 STAMFORD, Conn., Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the second quarter of fiscal 2026, which ended August 3, 2025. Shawn Nelson, Chief Executive Officer, stated, “We're pleased to have delivered another quarter of market share gains under...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

The Lovesac Company Announces Second Quarter Conference Call Date

The Lovesac Company Announces Second Quarter Conference Call Date STAMFORD, Conn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its second quarter financial results will be released before market open on Thursday, September 11, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-4...

 PRESS RELEASE

The Lovesac Company Appoints Alan Boehme to Its Board of Directors

The Lovesac Company Appoints Alan Boehme to Its Board of Directors STAMFORD, Conn., Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced that Alan Boehme has been appointed to the Board of Directors, effective August 27, 2025. Andrew Heyer, Chairman of the Board of Directors, stated, "We are thrilled to welcome Alan to our Board. His exceptional track record of driving digital transformation, operational excellence,...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Stephane Foucaud
  • Stephane Foucaud

AUCTUS ON FRIDAY - 08/08/2025

AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: High production at Z&G. Low risk exploration drilling in Austria to start in 4Q25/1Q26 – 2Q25 net production of 303 boe/d was higher than our expectations of ~270 boe/d following a 5 well intervention programme at the Zisterdorf and Gaiselberg fields in the Vienna Basin. The programme included (1) repair of subsurface equipment, (2) clean out of a down hole sand control (3) perfor...

Filipe Botelho ... (+3)
  • Filipe Botelho
  • Josseline Jenssen
  • Lorena Reich

Lucror Analytics - Morning Views Latam

In today's Morning Views publication we comment on developments of the following high yield issuers: TGS, Geopark, Embraer, Gran Tierra Energy, Klabin, Pemex, YPF, BRF, Aegea

Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Lorena Reich

Lucror Analytics - Morning Views Latam

In today's Morning Views publication we comment on developments of the following high yield issuers: Gran Tierra Energy, CSN, Gerdau, Nexa, Vale, Volcan, GOL

Stephane Foucaud
  • Stephane Foucaud

AUCTUS ON FRIDAY - 01/08/2025

AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: Operating update – Net production in Austria was 303 boe/d. The company held A$4.8 mm in cash at the end of June. Criterium Energy (CEQ CN)C; Target price of C$0.35 per share: Successful flow test at North-MGH boosts expected 2H26 gas production to 7-10 mmcf/d – The MGH-20 well in the North Mengoepeh (MGH) field tested 2.8 mmcf/d with associated oil. This is a positive surprise a...

 PRESS RELEASE

OPKO Health Reports Second Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...

Filipe Botelho ... (+3)
  • Filipe Botelho
  • Josseline Jenssen
  • Lorena Reich

Lucror Analytics - Morning Views Latam

In today's Morning Views publication we comment on developments of the following high yield issuers: Nemak, Gran Tierra Energy, Aeromexico, Embraer, Braskem

 PRESS RELEASE

OPKO Health to Report Second Quarter 2025 Financial Results on July 31

OPKO Health to Report Second Quarter 2025 Financial Results on July 31 MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on July 31 beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-re...

MarketLine Department
  • MarketLine Department

SL Green Realty Corp. - Mergers & Acquisitions (M&A), Partnerships & A...

Summary Marketline's SL Green Realty Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by SL Green Realty Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Inv...

 PRESS RELEASE

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Ta...

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. A...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch